ETHIOPIAN PUBLIC HEALTH INSTITUTE
           REFERENCE MANAGEMENT SYSTEM
Subscribe to RSS feed
                                

WIKINDX Resources

Gebre-Hiwot, A., Tadesse, G., Croft, S. L., & Frommel, D. (1992). An in vitro model for screening antileishmanial drugs: The human leukaemia monocyte cell line, thp-1. Acta Tropica, 51(3-4), 237–245. 
Resource type: Journal Article
DOI: 10.1016/0001-706X(92)90042-V
ID no. (ISBN etc.): 0001706X
BibTeX citation key: GebreHiwot1992
View all bibliographic details
Categories: General
Keywords: Antileishmanial drugs, Leishmania aethiopica, Leishmania donovani, THP-1 cell line
Creators: Croft, Frommel, Gebre-Hiwot, Tadesse
Collection: Acta Tropica
Attachments   URLs   https://linkinghub ... i/0001706X9290042V
Abstract
Standard anti-leishmanial drugs were tested for their ability to inhibit the growth of intracellular amastigotes of Leishmania aethiopica, L. donovani and L. infantum in the human leukemia monocyte THP-1 cell line. Sodium stibogluconate and meglumine antimoniate were active against L. donovani with ED50 values of 8.9 $μ$g Sbv/ml and 2.9 $μ$g Sbv/ml, respectively. L. aethiopica was less sensitive to sodium stibogluconate with an ED50 value of 25.3 $μ$g Sbv/ml while pentamidine had an ED50 value of 0.6 $μ$M. Both L. donovani (ED50, 9.3 $μ$M), and L. aethiopica (ED50, 6.4 $μ$M), were sensitive to aminosidine sulphate. An L. infantum isolate, clinically resistant to meglumine antimoniate treatment, had an ED50 of 22.2 $μ$g Sbv/ml. The toxic level of drugs on host cells was determined by colorimetric Methyl Tetrazolium (MTT) assay prior to activity tests. The results obtained with the THP-1 in vitro drug screening model were similar to those obtained in the mouse peritoneal macrophage model. ©1992.